View all veterinary jobs
MSD Animal Health UK has announced the launch of Bravecto, which it says is the first and only treatment available for fleas and ticks in dogs that is rapidly effective and offers 12-weeks duration of efficacy.
Bravecto (fluralaner) is the first of a new generation of systemically active ectoparasiticides, the isoxazolines, and will only be available on prescription through veterinary practices. The new product will be available in five strengths of pork liver flavoured palatable chew for different size dogs - one chew per weight band - which MSD says are readily accepted from the hand. Jolian Howell, marketing and technical lead at MSD Animal Health UK said: "Bravecto is a truly unique and exciting innovation which will transform the effective treatment of fleas and ticks - providing protection like never before from a single dose. It is the first in a new generation of products that offer a full 12-week protection and will help keep the treatment of fleas and ticks within veterinary practices."
He continued: "Estimates suggest that flea and tick treatments are applied for just 2.8 months per year so just one dose of Bravecto will immediately deliver much improved levels of treatment for dogs in veterinary care, which is good for the animal and good for the vet." MSD Animal Health says it is investing in the launch of Bravecto with a major marketing and practice support package which aims to raise awareness of fleas and ticks and drive pet owner footfall into practices for flea and tick control.
The new product will be available after BSAVA Congress, where MSD will be giving visitors the opportunity to learn more about it.